Incretin-Based therapy for type 2 diabetes: overcoming unmet needs

Size: px
Start display at page:

Download "Incretin-Based therapy for type 2 diabetes: overcoming unmet needs"

Transcription

1 2 : 15 Incretin-Based therapy for type 2 diabetes: overcoming unmet needs Diabetes is a progressive disease characterised by impaired betacell function, and reduced insulin sensitivity and secretion. Over time, glycaemic control deteriorates and exacerbates the risk of patients experiencing micro- and macrovascular complications (UKPDS, 1998). Although there is an abundance of treatment options and guidelines available for the management of type 2 diabetes, they are unable to avert the natural progression of the disease and sustain glycaemic control in the long term. Furthermore, currently available treatment options (such as sulphonylureas, thiazolidinediones and most insulins) are often associated with hypoglycaemia and weight gain, (Kahn et al.,26; UKPDS et al., 1998: Figure 1 and 2). Such adverse effects can have detrimental health implications for the patient. For example, hypoglycaemia can be an unpleasant side-effect of anti-diabetic therapy which can compromise patient adherence to treatment, and serious hypoglycaemic events, left untreated, can lead to a loss of Patients with hypoglycaemia (%) p<.5 glibenclamide vs. rosiglitazone 1 12 Rosiglitazone Metformin Glibenclamide Fig. 1 : Hypoglycaemia 39 Patients self-reporting (unconfirmed) hypoglycaemia Klaus Henning Jensen, Denmark consciousness, brain damage or even death. Moreover, obesity is a common co-morbidity in subjects with type 2 diabetes (6-9% of patients diagnosed). Additional weight gain as a consequence of treatment with SU s or insulin for example, can reduce patients quality of life and hinder adherence to treatment. Obesity is also an independent risk factor for cardiovascular disease, further compromising patient outcomes (Hubert et al., 1983; Han et al., 1998; Odegard et al., 27). The greatest challenge in treating patients with type 2 diabetes is optimising therapy to address the current unmet needs: improve glycaemic control without compromising safety i.e. hypoglycaemia preserve beta-cell function provide clinically meaningful weight loss address CV risk factors accompanying diabetes offer a simple and flexible regimen GLP1 receptor agonists may provide solutions to all of these challenges. Change in weigh (kg) UKPDS: up to 8 kg in 12 years 8 7 Insulin (n=49) 7 5 Glibenclamide (n=277) Metformin (n=342) Years from randomisation Conventional treatment (n=411); diet initially then sulphonylurea, insulin and/or metformin if FPG >15 mmol/l weight (kg) ADOPT : up to 4.8 kg in 5 years 1 Fig. 2 : Weight gain over time Years Rosiglitazone Metformin Glibenclamide UKPDS 34, Lancet 1998:352: n=at baseline; Kahn et al (ADOPT). NEJM 26;355(23):

2 Medicine Update 21 Vol. 2 plasma insulin secretion observed with oral vs. intravenous glucose administration despite matching glucose profiles (Figure 3). The incretin effect is blunted in subjects with type 2 diabetes (Nauck et al., 1986; Figure 3c). In patients with type 2 diabetes, GLP-1 infusion (but not GIP) markedly improves both the early and late phases of insulin secretion in response to glucose (Vilsboll et al., 22, Hojberg et al., 28). As such, it is GLP-1 rather than GIP that has been the focus of research as a promising treatment for type 2 diabetes. Fig. 3 : Incretin effect Background to the incretin effect GLP-1 and GIP are gut-derived, receptor-specific hormones, known as incretins. The increctin hormones have multiple physiological actions; most importantly they play a crucial role in glucose homeostasis. The action of the incretin hormones accounts for 5 7% of insulin secretion after oral glucose intake. This incretin effect is characterised by the more pronounced GLP-1 and its relevance to treating the unmet needs in T2D The action of GLP-1 on beta-cell receptors enhances insulin secretion in a glucose dependant manner (Nauck et al., 1993) which, in turn minimises the risk of hypoglycaemia. In addition, animal studies have indicated that GLP-1 has the ability to preserve beta-cell function by suppressing beta-cell apoptosis and stimulating neogenesis and proliferation (Bulotta et al., 22, Farilla et al., 23). Other clinical advantages associated with GLP-1 may be explained by its hormonal influences on the gastrointestinal, CNS and CV systems (Figure 4). GLP-1 has demonstrated the ability to slow gastric emptying and suppress appetite, resulting in satiety and weight loss. GLP-1 also appears to exert a protective effect on the myocardium, particularly in ischaemic conditions. For example, Bose and colleagues reported that an intravenous infusion of GLP-1 in rats, prior to induced ischaemia significantly reduced myocardial infarction compared with saline (Bose et al., 25). Studies have also reported improved myocardial function in patients with type 2 diabetes and congestive heart failure (Thrainsdottir et al 24), and infusion of recombinant GLP-1 has been shown to improve left ventricular function in patients with acute myocardial infarction after primary angioplasty (Nikolaidis Mankad et al 24). Improvement in endothelial function has also been reported with GLP-1; a significant increase in brachial artery diameter was observed in patients with type 2 diabetes (Nystrom et al 24). Furthermore, GLP-1 has been found to reduce systolic blood pressure (SBP). This may be, in part, due to its ability to increase diuresis and natiuresis, thus reducing blood volume and central venous pressure. This is an important observation, since CV disease is a common co-morbidity of type 2 diabetes, and a mean reduction in systolic blood pressure (SBP) of 5.6 mmhg has been shown to reduce mortality from the disease by 18% (Patel et al., 27). Clinical limitations of GLP-1 due to the presence of DPP-4 As active GLP-1 is secreted from L-cells in the distal small intestine, it is rapidly degraded by the enzyme dipeptidyl peptidase IV (DPP-4). An i.v. bolus of GLP-1 has a half-life of minutes 16

3 Incretin-Based Therapy for Type 2 Diabetes: Overcoming Unmet Needs Pancreas Insulin secretion (glucose-dependent) and beta-cell sensitivity Insulin synthesis Glucagon secretion (glucose-dependent) Beta-cell mass Brain Energy intake Liver GI tract Decreased motility Fig. 4 : Physiological pathways of GLP-1 meaning that a constant infusion of GLP-1 is required to provide any therapeutic value. Development of liraglutide Human GLP-1 Liraglutide Enzymatic degradation by DPP-4 Renal clearance t 1/2 = min Knudsen et al. J Med Chem 2;43: % homology to human GLP-1 Improved PK: albumin binding and self-association Slow absorption from subcutis Resistant to DPP-4 Long plasma half-life (t 1/2 =13h) acting GLP-1 agents such as liraglutide have been developed. Liraglutide is an analogue of native human GLP-1, in which Lys 34 has been substituted with Arg 34 at the N-terminal and a fatty acid chain added to Lys 26. These modifications mean that liraglutide shares 97% amino acid identity with native human GLP-1 compared with exenatide (a GLP-1 mimetic) which shares just 53% sequence identity. Liraglutide s fatty acid side chain allows it to self-associate and form heptamers. The size of the heptamer and the strong self-association allow liraglutide to be absorbed slowly via the subcutaneous route (Knudsen et al., 2). Maximum plasma concentration levels are achieved between 9 12 h after dosing (Elbrond et al., 22).The fatty acid moiety also allows liraglutide to bind to serum albumin in the bloodstream (Steensgaard 28) and 36 Liraglutide monotherapy vs. SU LEAD 3 Liraglutide+MET vs. SU+MET LEAD 2 Liraglutide+SU vs. TZD+SU LEAD 1 Diet/exercise Start an oral agent Add another oral agent Add a thrid oral or start insulin Fig. 7: Liraglutide implementation throughout the continuum of care In order to overcome the short half-life of native GLP-1, longer- Liraglutide is a once-daily, human GLP-1 analogue resist DPP-4 degradation, resulting in a half-life of approximately 13 hours (Agersø et al, 22). These properties make liraglutide suitable for once-daily dosing (Agersø et al, 22). Clinical effects of liraglutide Liraglutide+MET+TZD vs. MET+TZD LEAD 4 Liraglutide+METand/orSU vs. exenatide+met and/or SU LEAD 6 Liraglutide+MET vs. sitagliptin+met 186 The phase 3a development programme for liraglutide, LEAD ( Liraglutide Effect and Action in Diabetes ), is the largest clinical development programme ever conducted by Novo Nordisk in diabetes. LEAD included 6 trials and was designed to investigate the efficacy and safety of liraglutide across the continuum of care of type 2 diabetes versus placebo. In the LEAD trials, liraglutide was also compared against some commonly used anti-diabetic therapies. An additional head-to-head trial against exenatide (LEAD-6) was also completed (Figure 7). HbA 1c, FPG and PPG The LEAD programme demonstrated that liraglutide, used as monotherapy or in with one or two OADs, provides substantial reductions in HbA 1c. Liraglutide reduced HbA 1c levels to a significantly greater extent than its active comparators, with LEAD-2 as the exception, in which HbA 1c reductions with 17

4 Medicine Update 21 Vol. 2 Fig. 8: Percentage of subjects reaching target ADA <7.% in the LEAD 1-6 trials Baseline category of HbA 1c n= n= n= n= n= n=187 Change in HbA 1c (%) Liraglutide 1.8 mg Rosiglitazone Glimepiride Glargine Exenatide Placebo n=1363 n=231 n=49 n=232 n=231 n=524 p<.1 vs liraglutide 1.8 mg Fig. 9: Meta-analysis of LEAD 1-6 showing HbA 1c reduction from baseline according to baseline category of HbA 1c liraglutide were comparable to glimepiride plus metformin (-1.%). Reductions in HbA 1c across the LEAD trials ranged from.84 to 1.6% with the highest doses of liraglutide (1.2 mg and 1.8 mg) relative to baseline (Marre et al., 29; Nauck et al., 29; Garber et al., 29; Zinman et al., 29; Russell-Jones et al., 28; Buse et al., 29). These reductions corresponded with a higher percentage of subjects in the liraglutide-treated groups reaching target HbA 1c <7.% in all LEAD studies compared with active comparators (Figure 8). The greatest reduction in HbA 1c (%) was experienced in the LEAD-3 trial (liraglutide monotherapy) by the subgroup of patients previously on diet and exercise: the true initial monotherapy population (Garber et al., 29). In the head-to-head study of liraglutide 1.8 mg once daily vs. exenatide 1 μg twice daily (as addon to metformin and/or SU therapy), mean HbA 1c reduction was significantly greater with liraglutide treatment than with exenatide: 1.12% versus.79%, p<.1 (Buse et al., 29). A meta-analysis of LEAD trials 1-6 concluded that liraglutide provides the greatest reductions HbA 1c in those patients with the highest HbA 1c levels at baseline (Figure 9). Liraglutide also provided substantial reductions in FPG across the continuum of care. FPG reductions of up to -2.4 mmol/l were reported with liraglutide across the LEAD 1-6 studies ((Marre et al., 29; Nauck et al. 29, Garber et al., 29; Zinman et al., 29; Russell-Jones et al., 28, Buse et al., 29): Figure 1). Liraglutide was also shown to be effective at reducing postprandial glucose; consistent reductions were observed in peak PPG (across all 3 meals) in LEAD 1-5 studies (Marre et al., 29; Nauck et al. 29, Garber et al., 29; Zinman et al., 29; Russell-Jones et al., 28). In the LEAD-6 study, there was a greater reduction in mean PPG after lunch with liraglutide compared with exenatide (

5 Incretin-Based Therapy for Type 2 Diabetes: Overcoming Unmet Needs Monotherapy LEAD-3 MET LEAD-2 SU LEAD-1 MET + TZD LEAD-4 MET + SU LEAD-5 MET + SU LEAD-6 Baseline FPG Fig. 1 : Change in FPG (mmol/l) in the LEAD 1-6 studies Improving beta-cell function Change in HbA 1C from baseline (%) <22.3 Liraglutide 1.2 mg HOMA-B (%) < >65.3 Liraglutide 1.8 mg Glimepiride Placebo # p=.5 liraglutide 1.8 mg vs. glimepride; p=.1 liraglutide 1.2 mg vs. glimepriride; p=.3 liraglutide 1.8 mg vs. glimepiride; p=.2 liraglutide 1.2 mg vs. glimepiride; # p=.3 glimpiride > vs. glimepiride < group Liraglutide significantly different to placebo for all quartiles (p<.1) Fig. 11: versus 2.35; NS). However, exenatide is given twice daily, before morning and evening meals, thus PPG was reduced more with exenatide vs liraglutide during these peak times (Buse et al., 29). Beta-cell function The LEAD trials have reported increases in beta-cell function (as measured by HOMA-B) of 28-34% from baseline after liraglutide treatment (Marre et al., 29; Nauck et al. 29, Garber et al., 29; Zinman et al., 29; Russell-Jones et al., 28, Buse et al., 29). As demonstrated by meta-analysis, the ability of liraglutide to lower HbA 1c remains substantial regardless of baseline HOMA-B (Figure 11). Weight Treatment with liraglutide significantly reduced weight in the A quarter of patients lose an average of 7.7 kg with liraglutide Weight change (kg) Q1 Q1-Q2 Q2-Q3 Q3-Q4 Liraglutide 1.8 mg + met + SU -Q1: mean weight change for the 25% of subjects who had the largest weight loss Q1-Q2: mean weight change for the 25-5% weight loss quartile Q2-Q3: mean weight change for the 5-75% weight loss quartile Q3-Q4: mean weight change for the 75-1% weight loss quartile, that is, the 25% who had the smallest weight loss Nuack et al. Diabetes Care 29;32;84-9 (LEAD-2) 19

6 Medicine Update 21 Vol. 2 Monotherapy LEAD-3 MET LEAD-2 SU LEAD-1 MET + TZD LEAD-4 MET + SU LEAD-5 MET ± SU LEAD-6 Change in SBP (mmhg) Liraglutide 1.2 mg Liraglutide 1.8 mg Glimepiride Rosiglitazone Glargine Exenatide Table 1: Change in SBP by mean baseline quartile Quartile, mmhg (Baseline) p<.1, p<.1, p<.5 versus baseline Liraglutide 1.8 mg (n = 1363) Liraglutide 1.2 mg (n = 896) LEAD 1 6 trials. Liraglutide has a more positive effect on weight than active comparators (Marre et al., 29; Nauck et al. 29, Garber et al., 29; Zinman et al., 29; Russell-Jones et al., 28) and was similar to the weight reductions reported with exenatide(buse et al., 29). Weight loss also appears to be sustained; a reduction of kg was reported in patients treated with liraglutide 1.8 mg monotherapy (LEAD-3, Garber et al., 29). The majority of this weight loss occurred primarily in the first 16 weeks and was maintained throughout the 52-week study period. In this trial, weight reduction was significantly greater with liraglutide vs. glimepiride (+1.12 kg, p<.1; Garber et al., 29). Furthermore, weight loss has been demonstrated to increase with increasing baseline body mass index (BMI). This is of particular advantage in obese subjects and, and those at greater risk of developing CV disease, since they would appear to experience greater weight loss than leaner patients (Russell-Jones et al. 28). Of note, an analysis of body composition (measured by dual energy X-ray absorptiometry (DEXA)) in subjects from the LEAD 2 study suggested that the majority of weight loss observed with liraglutide was due to fat loss; 86% of weight loss reported was fat tissue and the majority of this was found to be visceral (Jendle Fig. 12: Change in SBP across LEAD 1-6 trials Placebo (n = 524) Q1 8 to (1.) +5.4 (1.1) +7.1 (1.3) Q2 12 to 13.4 (.9) +.4 (1.1) +.9 (1.3) Q3 13 to (1.) 6.2 (1.1) 2.4 (1.3) Q4 14 to (1.) 11.4 (1.2) 7.7 (1.3) Effect on SBP with baseline SBP quartile was significant (p<.1) Greatest reduction observed in quartile with highest SBP Fonseca et al. Diabetes 29, 58 (Suppl 1): 545-P Patients reaching target (%) 45 LEAD studies 4 39% 35 32% % % 1 8%, 6%, 8%, 5 Liraglutide Liraglutide SU TZD Glargine Exenatide Placebo 1.8 mg 1.2 mg (n=1363) (n=896) (n=49) (n=231) (n=232) (n=231) (n=524) Liraglutide 1.8 mg is superior (p<.1; P<.1) Liraglutide 1.2 mg is superior ( p<.1) Percentages are from logistic regression model adjusted for trial, previous treatment and with baseline HbA 1C and weight as covariates Fig. 13: Percentage of subjects reaching HbA 1c target of <7.% with no hypoglycaemic events and no weight gain et al., 28). Systolic blood pressure Liraglutide provides clinically significant reductions in SBP and has been demonstrated across all LEAD trials (Marre et al., 29; Nauck et al., 29; Zinman et al., 29; Russell-Jones et al., 28, Buse et al., 29; Figure 12). SBP has also been shown to improve rapidly (as early as 2 weeks) following liraglutide initiation, and prior to significant treatmentinduced weight loss. As demonstrated in the meta-analysis, the effect on SBP with baseline SBP quartile was significant (p<.1), since the greatest reduction observed was in that with the highest SBP (Table 1). 11

7 Incretin-Based Therapy for Type 2 Diabetes: Overcoming Unmet Needs Safety and tolerability Since liraglutide acts in a glucose-dependent manner (Nauck et al., 23) the risk of hypoglycaemia is low. Throughout all the LEAD trials major hypoglycemia was rare; of the 6 cases reported, one of these patients was undergoing treatment with liraglutide 1.8 mg plus glimepiride (Marre et al., 29) and the other five were treated with liraglutide 1.8 mg in with glimepiride and metformin (Russel-Jones et al. 28). Since hypoglycaemic risk is a recognised feature of SU treatment we can assume these reports are a consequence of combining liraglutide with SU. Indeed, when liraglutide was used in with OADs (other than SUs) and as monotherapy, no major hypoglycaemia was observed (Nauck et al. 29, Garber et al., 29; Zinman et al., 29, Buse et al., 29). Minor hypoglycaemia is not uncommon with existing diabetes treatments, however, there was a lower number of minor hypoglycemia events reported with liraglutide treatment compared to that encountered with conventional diabetes treatments. To exemplify this, reports of minor hypoglycaemia with liraglutide 1.2 mg and 1.8 mg was at placebo level and lower than glimepiride treatment in the LEAD 2 study:.3 and.9 events/patient/year (liraglutide 1.2 mg and 1.8 mg, respectively) vs..13 (placebo) and 1.23 events/patient/year (glimepiride) (Nauck et al., 29). Overall, liraglutide is generally well tolerated with most adverse events across the LEAD studies reported as mild or moderate in severity and frequently gastrointestinal- related. Nausea was the most common adverse effect; it was reported by up to 4% of patients but tended to dissipate after a period of 4 weeks (Marre et al., 29; Nauck et al. 29, Garber et al., 29; Zinman et al., 29; Russell-Jones et al., 28, Buse et al., 29). This may be explained by liraglutide s ability to delay gastric emptying. Of note, very few adverse effects were serious and withdrawals were rare; majority of these withdrawals were due to nausea (Marre et al., 29; Nauck et al. 29, Garber et al., 29; Zinman et al., 29; Russell-Jones et al., 28, Buse et al., 29). Conclusion The role of GLP-1 receptor agonists as a treatment option for type 2 diabetes is rapidly evolving. Liraglutide, the first human GLP-1 analogue, has the potential to overcome the shortcomings of conventional therapies and address the current unmet needs of patients with type 2 diabetes. Liraglutide has with the once daily administration demonstrated superior clinical efficacy and a favourable safety profile in recent clinical trials versus standard therapies; glycaemic control improved substantially with liraglutide and hypoglycaemia was uncommon. Moreover, there is indication that liraglutide may have a positive effect not only on beta-cell function, but also on betacell mass that implies potential long-term benefits. Liraglutide has also been found to promote weight loss and reduce SBP, which in turn, may reduce the risk of cardiovascular disease. For type 2 diabetes patients, liraglutide offers a new and flexible treatment alternative to standard therapies which may help to overcome the unmet needs of current therapies. References 1. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. (27). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice, 13(Suppl. 1), Bose AK, et al. Diabetes 25; 54: Bose et al. Diabetes 25;54: Bulotta et al. J Mol Endocrinol 22;29: Buse J, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett J, Zychma M, Blonde L; for the LEAD 6 study group. (29). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), Defronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D. (25). Effects of exenatide (exendin-4) on glycemic control and weight over 3 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L.B., Rolan, P., Sturis, J., Hatorp, V., Zdravkovic, M. (22). Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care, 25: Farilla et al. Endocrinology 23;144: Garber A, Henry R, Ratner R, Garcia-Hernadez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 28; DOI: 1.115/ S (8) (LEAD 3) 1. Han TS et al., Am J public health 1998;88; Højberg PV, et al. Diabetologia 29; 52: Jendle J, et al. Diabetes 28; 57 (Suppl.1): P Kahn et al. (ADOPT). NEJM 26;355(23): Knudsen LB, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2; 43: Marre, M., Shaw, J., Brändle, M., Bebakar, W.M., Kamaruddin, N.A., Strand, J., Zdravkovic, M., Le Thi, T.D., Colagiuri, S.; LEAD-1 SU study group. (29). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine, 26, Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., Zinman, B.; American Diabetes Association; European Association for Study of Diabetes. (29). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32(1), Nauck et al. Diabetologia 1986;29: Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H., Zdravkovic, M., Düring, M., Matthews, D.R.; LEAD-2 Study Group. (29). Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in with metformin in type 2 diabetes. Diabetes Care, 32, Nikolaidis, Mankad et al. Circulation 24;19: Nystrom et al. Regul Pept 25;125: Nyström T, et al. Am J Physiol Endocrinol Metab 24; 287: E

8 Medicine Update 21 Vol Nyström T, et al. Regul Pept 25; 125: Hubert HB et al., Circulation 1983;67: Odegard PS et al., Diabetes Educ 27;33: Russell-Jones D, Vaag A, Schmitz O et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP- 1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. Diabetes 28; 57(Suppl. 1): A159 (Abstract 536-P). 25. Thrainsdottir et al. Diab Vasc Dis Res 24;1: UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, Vilsbøll et al. Diabetologia 22;45: Zinman, B., Gerich, J., Buse, J.B., Lewin, A., Schwartz, S., Raskin, P., Hale, P.M., 29. Zdravkovic, M., Blonde, L. (29). Efficacy and safety of the human GLP- 1 analog liraglutide in with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care, 32,

Liraglutide: First Once-Daily Human GLP-1 Analogue

Liraglutide: First Once-Daily Human GLP-1 Analogue DRUG PROFILE KERALA MEDICAL JOURNAL Liraglutide: First Once-Daily Human GLP-1 Analogue Sreejith N Kumar Research Cell, IMA Kerala State, K-5, Kochar Road, Sasthamangalam Thiruvananthapuram* ABSTRACT Published

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 December 2009 VICTOZA 6 mg/ml solution for injection in pre-filled pen Pack size of two 3 ml pens (CIP: 396 323-6)

More information

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes

More information

Early treatment for patients with Type 2 Diabetes

Early treatment for patients with Type 2 Diabetes Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona

More information

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have

More information

Role of incretins in the treatment of type 2 diabetes

Role of incretins in the treatment of type 2 diabetes Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine

More information

Chief of Endocrinology East Orange General Hospital

Chief of Endocrinology East Orange General Hospital Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage

More information

Management of Type 2 Diabetes

Management of Type 2 Diabetes Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity

More information

Liraglutide, the first once-daily human GLP-1 receptor analogue

Liraglutide, the first once-daily human GLP-1 receptor analogue avances en Diabetología Revisión, the first once-daily human GLP-1 receptor analogue S. Madsbad Department of Endocrinology. Hvidovre University Hospital. Hvidovre and University of Copenhagen. Copenhagen

More information

Data from an epidemiologic analysis of

Data from an epidemiologic analysis of CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated

More information

Francesca Porcellati

Francesca Porcellati XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia

More information

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met)

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met) Diabetes Care Publish Ahead of Print, published online October 17, 2008 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus

More information

Expanding Treatment Options for Diabetes: GLP-1 Receptor Agonists. Copyright

Expanding Treatment Options for Diabetes: GLP-1 Receptor Agonists. Copyright CLINICAL Viewpoint Expanding Treatment Options for Diabetes: GLP-1 Receptor Agonists Advancements in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial

More information

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma

More information

Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP

Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the

More information

PROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT

PROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,

More information

Diabetes Management Incretin Mimetics

Diabetes Management Incretin Mimetics The Incretin System and Type 2 Diabetes Anthony H Barnett, MD Professor of Medicine, Consultant Physician, and Clinical Director of Diabetes and Endocrinology, University of Birmingham and Heart of England

More information

Glucagon-like peptide-1 (GLP-1) is an

Glucagon-like peptide-1 (GLP-1) is an THE NEW SCIENCE OF GLP-1: EFFECTS BEYOND GLUCOSE CONTROL Richard E. Pratley, MD ABSTRACT The incretin hormone, glucagon-like peptide- 1 (GLP-1) has well-characterized effects on glucose homeostasis that

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness

More information

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Multiple Factors Should Be Considered When Setting a Glycemic Goal Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent

More information

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,

More information

GLP-1 Agonists for Diabetes

GLP-1 Agonists for Diabetes Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital

What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning

More information

The prevalence of type-2 diabetes is increasing at

The prevalence of type-2 diabetes is increasing at Non-insulin injectable therapy The prevalence of type-2 diabetes is rapidly increasing with up to a quarter of people over 60 years of age affected it. To reduce the risk of the associated microvascular

More information

T2DM is a global epidemic with

T2DM is a global epidemic with : a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present

More information

Treatment Options for Diabetes: An Update

Treatment Options for Diabetes: An Update Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider

More information

Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes

Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring

More information

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy

More information

Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus

Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus Supplement issue Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD Diabetes and Metabolism Translational Medicine

More information

Liraglutide (Victoza)

Liraglutide (Victoza) Liraglutide (Victoza) The First Once-Daily Incretin Mimetic Injection For Type-2 Diabetes Sylvia H. Jackson, PharmD, CDE, MEd; Tonya S. Martin, PharmD, CGP, MAEd; Jocelyn D. Jones, PharmD, BCPS; David

More information

Non-insulin treatment in Type 1 DM Sang Yong Kim

Non-insulin treatment in Type 1 DM Sang Yong Kim Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay

More information

Glucagon-Like Peptide-1 (GLP-1) Agonists

Glucagon-Like Peptide-1 (GLP-1) Agonists Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes E m e r g i n g T r e a t m e n t s a n d T e c h n o l o g i e s O R I G I N A L A R T I C L E Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin,

More information

The first stop for professional medicines advice

The first stop for professional medicines advice London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1

More information

Volume : 05 Issue : 03 July-Sept Pages:

Volume : 05 Issue : 03 July-Sept Pages: Middle East Journal of Applied Sciences Volume : 05 Issue : 03 July-Sept. 2015 Pages: 695-699 Efficacy and Safety of Vildagliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Poorly Controlled

More information

(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2

(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2 007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase

More information

The Many Faces of T2DM in Long-term Care Facilities

The Many Faces of T2DM in Long-term Care Facilities The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and

More information

Update on Insulin-based Agents for T2D

Update on Insulin-based Agents for T2D Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment

More information

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes Thong, K.y.; Gupta, P. Sen; Blann, Andrew; Ryder, R.e.j. DOI:

More information

Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007

Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007 Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited

More information

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Richard E. Pratley and Matthew Gilbert

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Richard E. Pratley and Matthew Gilbert REVIEW Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors Richard E. Pratley and Matthew Gilbert Diabetes and Metabolism Translational Medicine Unit, University

More information

Type 2 diabetes and cardiovascular risk: the role of GLP-1

Type 2 diabetes and cardiovascular risk: the role of GLP-1 Type 2 diabetes and cardiovascular risk: the role of GLP-1 Dr Isidora Kitsou-Mylona, PhD Novo Nordisk Regional Medical Advisor Business Area Africa, Gulf & India Disclaimer I am an employee of Novo Nordisk

More information

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Timely!Insulinization In!Type!2! Diabetes,!When!and!How Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for

More information

Professor Rudy Bilous James Cook University Hospital

Professor Rudy Bilous James Cook University Hospital Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6

More information

Diabetes: Three Core Deficits

Diabetes: Three Core Deficits Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet

More information

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical

More information

SELECTED ABSTRACTS AND POSTER PRESENTATIONS

SELECTED ABSTRACTS AND POSTER PRESENTATIONS SELECTED ABSTRACTS AND POSTER PRESENTATIONS The following summaries are based on abstracts and posters presented at the American Diabetes Association s 65th Annual Scientific Sessions held in San Diego,

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

Optimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy

Optimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world

More information

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight

More information

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE

More information

22 Emerging Therapies for

22 Emerging Therapies for 22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.

More information

Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes

Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative

More information

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011

More information

Abstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah

Abstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes

More information

Pramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon

Pramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant

More information

New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy

New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program

More information

Glycemic control what can be achieved with life-style and when and how to use pharmacological agents?

Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key

More information

Achieving and maintaining good glycemic control is an

Achieving and maintaining good glycemic control is an Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,

More information

GLP-1-based therapies in the management of type 2 diabetes

GLP-1-based therapies in the management of type 2 diabetes GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin

More information

RESEARCH. What this study adds. What is already known about this subject

RESEARCH. What this study adds. What is already known about this subject RESEARCH Evaluating the Short-Term Cost-Effectiveness of Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States Jakob Langer, MSc; Barnaby Hunt, BSc; and

More information

Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM

Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes

More information

GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.

GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North

More information

Drugs used in Diabetes. Dr Andrew Smith

Drugs used in Diabetes. Dr Andrew Smith Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin

More information

T here is a progressive deterioration in

T here is a progressive deterioration in D I A B E T E S T R E A T M E N T S Incretin Effects on b-cell Function, Replication, and Mass The human perspective ALAN J. GARBER, MD, PHD T here is a progressive deterioration in b-cell function in

More information

Clinical Overview of Combination Therapy with Sitagliptin and Metformin

Clinical Overview of Combination Therapy with Sitagliptin and Metformin Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy

More information

Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes

Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes Adv Ther (2013) 30(2):81 101. DOI 10.1007/s12325-013-0009-4 REVIEW Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes Michael Horowitz Christopher K. Rayner Karen L.

More information

To evaluate the efficacy of GLP-1 analogues on the blood sugar levels, insulin resistance, islet β-cell function and pre-diabetes of the children.

To evaluate the efficacy of GLP-1 analogues on the blood sugar levels, insulin resistance, islet β-cell function and pre-diabetes of the children. Biomedical Research 2017; 28 (10): 4460-4465 ISSN 0970-938X www.biomedres.info To evaluate the efficacy of GLP-1 analogues on the blood sugar levels, insulin resistance, islet β-cell function and pre-diabetes

More information

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes Elmer ress Original Article J Clin Med Res. 2015;7(9):694-699 Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes Daisuke Ito a, b, d, Takujiro Iuchi a, Susumu

More information

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell

More information

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the

More information

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million

More information

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis

More information

Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus

Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes

More information

la prise en charge du diabète de

la prise en charge du diabète de N21 XIII Congrès National de Diabétologie, 29 mai 2011, Alger Intérêt et place des Anti DPP4 dans la prise en charge du diabète de type 2 Nicolas PAQUOT, MD, PhD CHU Sart-Tilman, Université de Liège Belgique

More information

MOA: Long acting glucagon-like peptide 1 receptor agonist

MOA: Long acting glucagon-like peptide 1 receptor agonist Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication

More information

Diabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy

Diabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism

More information

The design of the liraglutide clinical trial programme

The design of the liraglutide clinical trial programme review article Diabetes, Obesity and Metabolism 14 (Suppl. 2): 4 12, 2012. 2012 Blackwell Publishing Ltd The design of the liraglutide clinical trial programme M. A. Nauck Diabeteszentrum Bad Lauterberg,

More information

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management

More information

UKPDS: Over Time, Need for Exogenous Insulin Increases

UKPDS: Over Time, Need for Exogenous Insulin Increases UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin

More information

exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited

exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed

More information

Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes

Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes PhD Thesis Abstract Key words:

More information

Liraglutide for the treatment of diabetes mellitus in Japan

Liraglutide for the treatment of diabetes mellitus in Japan REVIEW Liraglutide for the treatment of diabetes mellitus in Japan Kohei Kaku Practice Points A once-daily 0.9 mg dose of liraglutide administered to Japanese subjects with Type 2 diabetes mellitus provides

More information

Newer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH

Newer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.

More information

Novel anti-diabetic therapies

Novel anti-diabetic therapies Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South

More information

GLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.

GLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4. GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells

More information

Evidence-Based Glucose Management in Type 2 Diabetes

Evidence-Based Glucose Management in Type 2 Diabetes Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine

More information

Efficacy of Liraglutide in a Real-Life Cohort

Efficacy of Liraglutide in a Real-Life Cohort Diabetes Ther (2014) 5:193 206 DOI 10.1007/s13300-014-0062-2 ORIGINAL RESEARCH Efficacy of Liraglutide in a Real-Life Cohort Anthony Heymann Yasmin Maor Inbal Goldstein Lora Todorova Perlit Schertz-Sternberg

More information

Current Status of Incretin Based Therapies in Type 2 Diabetes

Current Status of Incretin Based Therapies in Type 2 Diabetes Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine

More information

Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach

Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach Diabetes Ther (2014) 5:333 340 DOI 10.1007/s13300-014-0058-y COMMENTARY Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach Sanjay Kalra To view enhanced content

More information

By Eulalia Barajas-Graham

By Eulalia Barajas-Graham Clinical Review of Incretin Based Therapies: Their Role in the Management of Type 2 Diabetes Mellitus. By Eulalia Barajas-Graham A Capstone Paper submitted to the faculty of the University of North Carolina

More information

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017

More information

Oral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Oral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight

More information

IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes

IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes primary care diabetes 10 (2016) 202 209 Contents lists available at ScienceDirect Primary Care Diabetes journal homepage: http://www.elsevier.com/locate/pcd Review IDegLira: Redefining insulin optimisation

More information

Scope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors

Scope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล

More information

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D. Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is

More information

Changing Diabetes: The time is now!

Changing Diabetes: The time is now! Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison

More information